Arndt Rolfs is the CEO and founder of CENTOGENE AG, an international operating biotechnology diagnostic company and one of the global leaders in the characterization and diagnosis of rare hereditary disorders. As a Professor for Neurology he is specialized in clinical neurology and neurogenetics. He received approbation for human medicine in 1985 from the University of Mainz, Germany and got his habilitation in neuroinfectiology from University of Rostock, Germany. He is principle investigator of numerous international multicentre studies in the area of rare diseases, e.g. the world’s largest study in young stroke patients, the Sifap-project with more than 5,000 patients enrolled. Furthermore, Professor Rolfs is actively engaged in the development of new biomarkers for a broad spectrum of hereditary disorders, like Gaucher, MPS, Wolman, pancreatic carcinoma or Farber disease. He is author and coauthor of more than 200 peer-reviewed scientific publications and has contributed to multiple international patents. Professor Rolfs was founder of several German biotech companies and acted as a consultant for international biotech and industrial companies.